825 reports of this reaction
1.7% of all PAZOPANIB HYDROCHLORIDE reports
#15 most reported adverse reaction
HAIR COLOUR CHANGES is the #15 most commonly reported adverse reaction for PAZOPANIB HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 825 FDA adverse event reports linking PAZOPANIB HYDROCHLORIDE to HAIR COLOUR CHANGES. This represents approximately 1.7% of all 49,320 adverse event reports for this drug.
Patients taking PAZOPANIB HYDROCHLORIDE who experience hair colour changes should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAIR COLOUR CHANGES is a less commonly reported adverse event for PAZOPANIB HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hair colour changes, the following adverse reactions have been reported for PAZOPANIB HYDROCHLORIDE:
The following drugs have also been linked to hair colour changes in FDA adverse event reports:
HAIR COLOUR CHANGES has been reported as an adverse event in 825 FDA reports for PAZOPANIB HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAIR COLOUR CHANGES accounts for approximately 1.7% of all adverse event reports for PAZOPANIB HYDROCHLORIDE, making it a notable side effect.
If you experience hair colour changes while taking PAZOPANIB HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.